Delcath Continues Expansion of Clinical Trial Centers Offering PHP(TM)
09 April 2009 - 3:04PM
PR Newswire (US)
THE OHIO STATE UNIVERSITY COMPREHENSIVE CANCER CENTER JOINS PHASE
III TRIAL FOR METASTATIC MELANOMA NEW YORK, April 9
/PRNewswire-FirstCall/ -- Delcath Systems, Inc. (NASDAQ: DCTH)
announced today that The Ohio State University Comprehensive Cancer
Center - James Cancer Hospital and Solove Research Institute has
joined Delcath's Phase III clinical trial for the treatment of
metastatic melanoma in the liver. Ohio State is the twelfth center
to join this multi-center trial testing the Company's Percutaneous
Hepatic Perfusion (PHP(TM)) System for the isolated, high-dose
delivery of the anti-cancer agent melphalan. (Logo:
http://www.newscom.com/cgi-bin/prnh/20081118/NY46990LOGO ) Delcath
and Ohio State have entered into a clinical research agreement to
conduct the Phase III National Cancer Institute (NCI) led study.
Dr. Mark Bloomston, a surgical oncologist specializing in regional
cancer therapy, will serve as the Principal Investigator.
Commenting on joining this trial, Dr. Bloomston stated, "The
Delcath PHP System(TM) is a welcome addition to the currently
available therapies for liver cancer, and we look forward to
treating patients in this trial. Metastatic melanoma, once it
reaches the liver, has few viable treatment options. This
technology offers a very promising approach for targeting the
disease in the liver and we are eager to provide this modality to
our patients." Commenting on this twelfth center joining the trial,
Richard L. Taney, President and CEO of Delcath, stated, "We are
delighted to have Ohio State and Dr. Bloomston join this trial as
we continue to expand to an increasing number of leading cancer
centers in the United States. The prestige of these centers is a
validation of the need for a viable treatment option for these very
ill patients. Continuing to expand this trial assists in the
acceleration of enrollment, increases the awareness of the Delcath
PHP System(TM) among physicians, and expands patient access to
PHP(TM)." About The Ohio State University Comprehensive Cancer
Center - James Cancer Hospital and Solove Research Institute The
Ohio State University Comprehensive Cancer Center - James Cancer
Hospital and Solove Research Institute is one of only 40
NCI-designated Comprehensive Cancer Centers in the United States
and the only freestanding cancer hospital in the Midwest. Ranked
among the top 20 cancer hospitals in the nation, The James is the
172-bed adult patient-care component of the cancer program at The
Ohio State University. For more information, visit
http://www.jamesline.com/. About Delcath Systems, Inc. Delcath
Systems, Inc. is a medical technology company specializing in
cancer treatment. The Company is testing a proprietary, patented
drug delivery system for the treatment of liver cancers. Delcath's
novel drug delivery platform is testing the delivery of ultra-high
doses of anti-cancer drugs to the liver while preventing these high
doses of drug from entering the patient's bloodstream. The Company
is currently enrolling patients in Phase III and Phase II clinical
studies for the treatment of liver cancers using high doses of
melphalan. The Company's intellectual property portfolio consists
of twenty-seven patents on a worldwide basis including the U.S.,
Europe, Asia and Canada. For more information, please visit the
Company's website at http://www.delcath.com/. The Private
Securities Litigation Reform Act of 1995 provides a safe harbor for
forward-looking statements made by the Company or on its behalf.
This news release contains forward-looking statements, which are
subject to certain risks and uncertainties that can cause actual
results to differ materially from those described. Factors that may
cause such differences include, but are not limited to,
uncertainties relating to our ability to successfully complete
Phase III clinical trials and secure regulatory approval of our
current or future drug-delivery system and uncertainties regarding
our ability to obtain financial and other resources for any
research, development and commercialization activities. These
factors, and others, are discussed from time to time in our filings
with the Securities and Exchange Commission. You should not place
undue reliance on these forward-looking statements, which speak
only as of the date they are made. We undertake no obligation to
publicly update or revise these forward-looking statements to
reflect events or circumstances after the date they are made.
http://www.newscom.com/cgi-bin/prnh/20081118/NY46990LOGODATASOURCE:
Delcath Systems, Inc. CONTACT: Richard Taney of Delcath Systems,
Inc., +1-212-489-2100, ; or Public Relations, Robin Wagge of
Rubenstein Associates, Inc., +1-212-843-8006, Web Site:
http://www.delcath.com/ http://www.jamesline.com/
Copyright